{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:56:03Z","timestamp":1781585763850,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Plant Homeodomain Finger Protein 6 (PHF6) gene mutations are rare in acute myeloid leukemia (AML), with unclear mechanisms and uncertain prognostic value. They may compromise risk stratification and treatment decisions. This study analyzed clinical features and survival outcomes in\n                      <jats:italic>PHF6<\/jats:italic>\n                      \u2010mutated AML patients, evaluating the impact of allogeneic hematopoietic stem cell transplantation (HSCT) and co\u2010mutations on prognosis. Precise stratification helps optimize prognostic models and guide individualized therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study retrospectively analyzed 45 AML patients with\n                      <jats:italic>PHF6<\/jats:italic>\n                      gene alterations at our institution. Clinical features, treatment approaches, therapeutic outcomes, and gene co\u2010mutation profiles were comprehensively assessed to determine their prognostic significance. Overall survival (OS), disease\u2010free survival (DFS), and event\u2010free survival (EFS) among different groups were compared using the Kaplan\u2013Meier method and log\u2010rank test. A multivariate Cox regression model identified independent prognostic predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:italic>PHF6<\/jats:italic>\n                      \u2010mutated AML was associated with shorter OS compared with wild\u2010type (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), but\n                      <jats:italic>PHF6<\/jats:italic>\n                      mutation was not an independent predictor of OS in multivariate Cox analysis. HSCT improved OS, DFS, and EFS compared with no transplantation (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Median WBC at diagnosis was 2.04\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L; WBC \u2265\u20099.70\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L independently predicted poor prognosis.\n                      <jats:italic>RUNX1<\/jats:italic>\n                      co\u2010mutation correlated with shorter OS;\n                      <jats:italic>IDH1\/IDH2<\/jats:italic>\n                      co\u2010mutation with longer OS. Neither affected DFS or EFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      This study provides clinical evidence for prognosis assessment in\n                      <jats:italic>PHF6<\/jats:italic>\n                      \u2010mutated AML, enabling more precise risk stratification, individualized treatment, and further pathogenesis research.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71902","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:49:39Z","timestamp":1778046579000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying\n                    <scp>\n                      <i>PHF6<\/i>\n                    <\/scp>\n                    Mutations"],"prefix":"10.1002","volume":"15","author":[{"given":"Dongmei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6824-8320","authenticated-orcid":false,"given":"Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4160","authenticated-orcid":false,"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Zhejiang Hangzhou China"},{"name":"Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies  Zhejiang Hangzhou China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Zhejiang Hangzhou China"},{"name":"Cancer Center Zhejiang University  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.2662"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0571-x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24648"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0872-3"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009680"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.30"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00992-1"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26314"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.126"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003330"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17638"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01953-6"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03265-w"},{"issue":"1","key":"e_1_2_13_16_1","first-page":"28","article-title":"Myeloid Neoplasms With PHF6 Mutations: Context\u2010Dependent Genomic and Prognostic Characterization in 176 Informative Cases.Blood","volume":"15","author":"Fathima S.","year":"2025","journal-title":"Cancer Journal"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.212"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107044"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353118"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014103"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa626"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46134-w"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012519"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235150"},{"issue":"6","key":"e_1_2_13_25_1","article-title":"Acute Myeloid Leukemia With IDH1 and IDH2 Mutations: 2021 Treatment Algorithm.Blood","volume":"11","author":"Issa G. C.","year":"2021","journal-title":"Cancer Journal"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71902","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:21:42Z","timestamp":1781583702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cam4.71902"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71902","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71902"}}